Lumosa Therapeutics Co (ROCO:6535) GF Value Rank: 8 (As of Aug. 12, 2026) — 300% Above Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6535 Lumosa Therapeutics Co Ltd ROCO:6535
70 GF Score
Price NT$88.10
GF Value NT$128.07
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is Lumosa Therapeutics Co GF Value Rank?

Lumosa Therapeutics Co ROCO:6535 -4.34% 70 GF Value Rank is 8 as of Aug. 12, 2026, which is 300% above its 10-year median of 2.00. GuruFocus rates ROCO:6535 with a GF Score™ of 70/100 and a GF Value™ of NT$128.07 (Significantly Undervalued). The stock has 3 warning signs investors should review.

Lumosa Therapeutics Co has the GF Value Rank of 8.

GF Value Rank evaluates the exclusive GuruFocus valuation and performance of a stock, rated on a scale from 1 to 10. It is determined by the price-to-GF-Value (P/GF Value) ratio, a proprietary metric calculated based on historical multiples along with an adjustment factor based on a company's past returns and growth and future estimates of the business' performance.

GuruFocus found that for valuation, we cannot simply give stocks a better GF Value rank simply because they have a lower P/GF Value ratio. Backtesting shows that over the long term, the two worst-performing groups are the most expensive group (with the highest P/GF Value ratio) and the least expensive group (with the lowest P/GF Value ratio).

We can understand why the most expensive group underperforms. We were initially puzzled by the underperformance of the least expensive group, but we realized there is a reason why some stocks are super cheap. If they look too undervalued, it is often because the businesses behind them are poor quality. The market realized this and gave them low valuations. In a way, the market is efficient.

After multiple backtesting analyses, we granted the stocks in third-cheapest percentile the highest GF Value rank, as they have performed the best over a full market cycle. Stock performance is actually not as sensitive to valuation as it is to growth and profitability. On average, the companies in the 20%-50% valuation groups have similar performances. Therefore, we should avoid the most expensive and the least expensive stocks. We can be more tolerant of valuation.

A higher score indicates a stock with a relatively low valuation and substantial potential for outperformance. Conversely, a lower score often reflects stocks that are either highly overvalued or deeply undervalued, both of which tend to underperform.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.


Lumosa Therapeutics Co GF Value Rank Related Terms


ROCO:6535 vs VRTX, REGN, RVMD: GF Value Rank Comparison

For the Biotechnology subindustry, Lumosa Therapeutics Co's GF Value Rank, along with its competitors' market caps and GF Value Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lumosa Therapeutics Co GF Value Rank vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lumosa Therapeutics Co's GF Value Rank distribution charts can be found below:

* The bar in red indicates where Lumosa Therapeutics Co's GF Value Rank falls into.


ROCO:6535
70GF Score
Lumosa Therapeutics Co Ltd ROCO:6535
GF Value Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about GF Value Rank →
What does a GF Value Rank of 8 mean?
Lumosa Therapeutics Co (ROCO:6535) has a GF Value Rank of 8 as of Aug. 12, 2026. GF Value Rank is given based on historical multiples along with past returns, growth and future estimates of the business' performance. View historical data on Lumosa Therapeutics Co and its competitors. This is 300% above median its historical median of 2.00. Over the past decade, Lumosa Therapeutics Co's GF Value Rank has ranged from 1.00 to 10.00.
Is Lumosa Therapeutics Co's GF Value Rank too high?
Lumosa Therapeutics Co's current GF Value Rank of 8 is 300% above median its 10-year median of 2.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 10.00. Overall, Lumosa Therapeutics Co has a GF Score™ of 70/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Lumosa Therapeutics Co's GF Value Rank compare to VRTX and REGN?
Lumosa Therapeutics Co's GF Value Rank of 8 can be compared against companies in the Biotechnology industry. Historically, Lumosa Therapeutics Co's own GF Value Rank has ranged from 1.00 to 10.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Value Rank for a Biotechnology company?
A good GF Value Rank depends on the Biotechnology industry context. However, GF Value Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Value Rank mean?
A high GF Value Rank can signal that a stock is expensive relative to its fundamentals. GF Value Rank is given based on historical multiples along with past returns, growth and future estimates of the business' performance. View historical data on Lumosa Therapeutics Co and its competitors. Lumosa Therapeutics Co's current GF Value Rank is 8, which is 300% above median its own 10-year median of 2.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lumosa Therapeutics Co stock overvalued right now?
Based on GuruFocus' analysis, Lumosa Therapeutics Co (ROCO:6535) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$128.07, compared to a current price of NT$88.10 — trading 31.2% below its estimated fair value. The current GF Value Rank is 8, which is 300% above median its 10-year median of 2.00. Lumosa Therapeutics Co's overall GF Score™ is 70/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Value Rank calculated?
GF Value Rank is calculated from a company's financial statements. For Lumosa Therapeutics Co (ROCO:6535), the current GF Value Rank is 8 as of Aug. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lumosa Therapeutics Co (ROCO:6535) Overvalued in 2026?

Based on GuruFocus' analysis, Lumosa Therapeutics Co stock appears to be undervalued. The current stock price of NT$88.10 is trading 31.2% below its estimated GF Value™ of NT$128.07. GuruFocus considers Lumosa Therapeutics Co to be Significantly Undervalued.

Key valuation signals for ROCO:6535:

  • GF Value Rank: 8 (300% above median its 10-year median of 2.00)
  • GF Value™: NT$128.07 vs. price of NT$88.10 (31.2% below fair value)
  • GF Score™: 70/100 with 3 warning signs

No single metric tells the full story. See the ROCO:6535 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Lumosa Therapeutics Co Business Description

Address Park Street, 4th Floor, No. 3-2, Nangang District, Taipei, TWN, 11503
Lumosa Therapeutics Co Ltd develops new drugs. The company is engaged in the development of drugs for unmet medical needs in the fields of oncology and Neuroscience. Geographically, it derives a majority of its revenue from Taiwan and also has a presence in Asia, and America. The product pipeline of the company is Neuroscience, which includes LT 1001 for Postoperative Pain, LT 3001 for Acute Ischemic Stroke, LT 5001 for Uremic Pruritus, LT 6001 for Neurological disorder, and Oncology, including LT 2003 for Solid Tumor. It generates revenue from sales of goods.
70GF Score

Get the complete analysis for ROCO:6535

GF Value Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$88.10
Price
NT$128.07
GF Value